Cixutumumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Cixutumumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target IGF-1 receptor
Clinical data
Legal status
?
Identifiers
CAS number 947687-12-9 N
ATC code None
UNII 2285XW22DR YesY
KEGG D09328 YesY
Chemical data
Formula C6500H10052N1724O2036S44 
Mol. mass 146.3 kDa
 N (what is this?)  (verify)

Cixutumumab is a monoclonal antibody for the treatment of solid tumors.[1][2]

This drug was developed by ImClone Systems Inc. under the name IMC-A12.

It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.[3]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Cixutumumab American Medical Association.
  2. ^ McKian, KP; Haluska, P (2009). "Cixutumumab". Expert Opinion on Investigational Drugs 18 (7): 1025–33. doi:10.1517/13543780903055049. PMC 2939377. PMID 19548856. 
  3. ^ [1] National Cancer InstituteTemplate:Http://www.cancer.gov/drugdictionary/?CdrID=561575